Results 201 to 210 of about 22,252 (260)
The novel second-generation triterpenoid SCY-247 maintains <i>in vitro</i> and <i>in vivo</i> activity against resistant <i>Candida glabrata</i>. [PDF]
Antimicrob Agents ChemotherWiederhold NP +5 more
europepmc +1 more source
Endocrine consequences of antifungal therapy: A missed entity. [PDF]
World J Clin CasesThakkar S +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
International Journal of Antimicrobial Agents, 2019
OBJECTIVE The aim of this meta-analysis was to assess the efficacy and safety of treatment with echinocandins compared with amphotericin B in paediatric patients with invasive candidiasis.
Chih-Cheng Lai, Hung-Jen Tang
exaly +2 more sources
OBJECTIVE The aim of this meta-analysis was to assess the efficacy and safety of treatment with echinocandins compared with amphotericin B in paediatric patients with invasive candidiasis.
Chih-Cheng Lai, Hung-Jen Tang
exaly +2 more sources
Mycoses (Berlin), 2021
BACKGROUND Candida auris is an emerging, potentially multidrug-resistant pathogen that exhibits clade-specific resistance to fluconazole and also develops resistance to echinocandins and amphotericin B easily. This study analyzed 49 C. auris isolates for
M. Asadzadeh +6 more
semanticscholar +1 more source
BACKGROUND Candida auris is an emerging, potentially multidrug-resistant pathogen that exhibits clade-specific resistance to fluconazole and also develops resistance to echinocandins and amphotericin B easily. This study analyzed 49 C. auris isolates for
M. Asadzadeh +6 more
semanticscholar +1 more source
Pharmacotherapy, 2007
The changing pattern in fungal infections has driven the need to expand the targets of antifungal activity. The echinocandins are the newest addition to the arsenal against fungal infections. Three echinocandins have been approved by the United States Food and Drug Administration: caspofungin, micafungin, and anidulafungin.
Diane, Cappelletty +1 more
exaly +3 more sources
The changing pattern in fungal infections has driven the need to expand the targets of antifungal activity. The echinocandins are the newest addition to the arsenal against fungal infections. Three echinocandins have been approved by the United States Food and Drug Administration: caspofungin, micafungin, and anidulafungin.
Diane, Cappelletty +1 more
exaly +3 more sources
Mycoses (Berlin), 2021
The echinocandins, amphotericin B preparations, voriconazole and fluconazole are approved for the treatment of invasive candidiasis, though it remains unclear which agent is most effective.
Koray K Demir +6 more
semanticscholar +1 more source
The echinocandins, amphotericin B preparations, voriconazole and fluconazole are approved for the treatment of invasive candidiasis, though it remains unclear which agent is most effective.
Koray K Demir +6 more
semanticscholar +1 more source
New developments and directions in the clinical application of the echinocandins
Archives of Toxicology, 2017Christina C. Chang +3 more
exaly +2 more sources